First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. - Wikidata - wikimedia - TriplyDB

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

http://www.wikidata.org/entity/Q35111925

about

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Transforming growth factor β as regulator of cancer stemness and metastasis TGF-β signaling and its targeting for glioma treatment USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7 Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine Big opportunities for small molecules in immuno-oncology.Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.TGF-β1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT)Immunosuppressive mechanisms in glioblastoma.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes.Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Neuroinflammatory and autonomic mechanisms in diabetes and hypertension.Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor.Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.Efficacy of ALK5 inhibition in myelofibrosis.Transforming growth factor β and bone morphogenetic protein actions in brain tumors.Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.TGF-β signaling in liver and gastrointestinal cancers Signaling Receptors for TGF-β Family Members.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Pharmacological and immunological targeting of tumor mesenchymalization.Targeting TGF-β Signaling for Therapeutic Gain.Barriers to Radiation-Induced In Situ Tumor Vaccination.TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer.Cancer associated fibroblasts: An essential role in the tumor microenvironment.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers.Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.Glioma.LINE-1 couples EMT programming with acquisition of oncogenic phenotypes in human bronchial epithelial cells.Advances in immunotherapeutic research for glioma therapy.Obesity-associated extracellular mtDNA activates central TGFβ pathway to cause blood pressure increase.

P2860

Q26797238-96F5FD38-062A-464F-AD1C-9777794BB857 Q26798402-1EB37DA2-C5E5-456B-B403-16C929D4A32D Q28077319-87A6C8C0-C09D-4563-805B-42FEACCB6404 Q28082042-F0293AEB-2B07-4432-8D55-F228775F309A Q33625848-315FD406-DC78-48DA-8E52-1D4FA0C312F2 Q33755077-4A4F9007-39C7-4988-8F4F-656C60B25D0A Q34487689-07A6E855-4BF9-4DF1-ABE6-2A7FF31366B2 Q35289038-16D78841-6727-40C8-9BFC-00E81BF6B85E Q36121570-A423D314-DA10-4DE7-9622-6C2173EE37F9 Q36224048-D5F4C6E6-2108-4E8A-AE31-01AB02F0C905 Q36224057-C86FC9F6-BAEB-4F24-99F3-36DD38D9E69E Q36686638-6331109C-8FE4-4F61-910F-413BE6E70B28 Q37046781-BD875466-ED21-4DA8-8EBF-2CD1156AAD0D Q37079141-B66DA43F-7991-4626-8F9E-6B08F441F3A4 Q37139426-457689A5-B7B0-433A-9418-7B1A85A6A504 Q37183387-2AE67916-7078-4B1E-BD1A-25B23D7193B7 Q37488519-12CC7569-8AE7-4AE3-9F4F-897C255E1883 Q37503365-C50C5DAF-6E01-4CA9-89B3-32966867B688 Q37716369-D608C571-EB92-4F83-A1D2-4055A39F4A93 Q37730812-A8BDDAE0-74BE-4EE6-8334-75CEF7601892 Q38469127-0AA56D6F-202C-4381-8093-3B7A55578EAE Q38616707-D99C056C-0581-42D2-9A3B-77A07281073D Q38713844-B2485B2D-3512-41B6-8A75-63A86D9829A8 Q38719858-03DAB178-9FC4-4967-AF3B-2A00264B9D90 Q38765212-294C644E-4945-4653-B3E9-53B8083FC3F2 Q38796618-22B9F8C5-0C8A-46EB-A078-55D1939FD766 Q38915720-7EE8ABFD-6BCD-4057-A599-464613F06178 Q38996431-9270B083-7981-4FC6-AE6F-A2708E62C13E Q39029043-ABBBFC0A-BD95-4BB8-A299-742D2C5E4001 Q39155151-AF5EB08F-A819-46AC-991E-FD0ADCB55EB4 Q39203685-33C86EFD-DFD7-4EBB-AF68-92B009EA95FF Q41481557-4704C956-4F34-4345-BC4E-9C676CFF207B Q41614004-4B834443-D84C-453D-8C5C-C1DCB03C17A7 Q42113451-7BC6DE95-C2F5-4857-A6ED-A750CC84F1D4 Q42371554-9C3DD708-A4AE-4246-9362-C265AC91817D Q42380337-D00CACFF-DDED-448A-A551-AAE2D94B8CEA Q46820292-264B4664-7209-4D5E-9103-CD4C961B964F Q47131696-33F31099-EA9D-4DF1-9B59-65C04237EF02 Q47569046-084B0445-AFD7-4438-ADA8-E38DA7562B94 Q48414468-6FB3BAB4-094B-40D2-8ACB-AA39D4852E1F

P2860

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

http://www.wikidata.org/entity/Q35111925

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

First-in-human dose study of t ...... th advanced cancer and glioma.

@ast

First-in-human dose study of t ...... th advanced cancer and glioma.

@en

type

label

First-in-human dose study of t ...... th advanced cancer and glioma.

@ast

First-in-human dose study of t ...... th advanced cancer and glioma.

@en

prefLabel

First-in-human dose study of t ...... th advanced cancer and glioma.

@ast

First-in-human dose study of t ...... th advanced cancer and glioma.

@en

P1433

Q35111925-A642DF74-737D-439E-968B-C688E103BB46

P1476

Q35111925-65F14BFC-6E06-4F71-B6EF-131177E61FE6

P2093

Q35111925-0D53D47D-30D9-457A-A7C9-B810B900B1E1

Q35111925-0DE16887-555F-4E6B-9113-22D8D43823B4

Q35111925-22854E89-E949-45DF-9D68-E0D4B103C29D

Q35111925-2BF9CECF-DCFC-4EF7-9FBB-904340793005

Q35111925-45E4D367-3FFE-4305-88B0-85E162490C49

Q35111925-4CF305B3-8BB0-415B-B180-1BC14BC921B7

Q35111925-4E206B07-2416-4A3D-ADA5-D498FE43D166

Q35111925-5095ED62-C935-4819-9ADE-CE95006A0163

Q35111925-5CBFF4F4-903B-4FBE-8627-5E10481F4DFC

Q35111925-5D59A60E-D83E-40C6-9F1E-812258E362C7

P2860

Q35111925-0B32153E-3D98-4100-99F8-7ED8D80A4FF5

Q35111925-1B37DED9-67EB-49A8-AC9A-6FA4A386CF49

Q35111925-1C415008-DDED-43AB-A5B5-EF99B70FEE02

Q35111925-274F96D5-D7F7-4F91-933E-0970F6481EF7

Q35111925-287EABD4-256A-4DC9-879D-DD1C2BA20535

Q35111925-3A89A615-FBB4-45DF-9450-9CA3E73CD338

Q35111925-3F8AE788-7A7D-4BB0-A939-AFC299699526

Q35111925-4738D331-9107-4F94-9A98-A9509B535ED2

Q35111925-49DE8E8B-DFBE-4FF9-843F-90645D88316D

Q35111925-5EF02A2E-91F5-4EB4-94BD-71998FF60C30

P304

Q35111925-D04D1843-9788-4696-B857-C87D3BF39AD0

P31

Q35111925-5CA9D8C2-B9DA-4B91-B738-841B9FFC45C7

P356

Q35111925-71653F48-F323-4E1A-AD6F-46CDE2D3FFE8

P407

Q35111925-5663A559-1D7F-4CFC-8DF5-08F91DD539EB

P433

Q35111925-2F618BDB-8D31-4C56-BAC8-6C34F49DF286

P478

Q35111925-7B306456-74F0-43B5-925A-EEE348FB705D

P50

Q35111925-28A13811-7767-4FD0-8412-C753F42100C4

P577

Q35111925-4DEAFE4F-01D9-43E1-8F27-82CC78140EC8

P698

Q35111925-B4A07107-3C94-453D-98AC-F55D4AC3B134

P921

Q35111925-047601E3-E1B3-4F65-9DBE-864ED44F1384

P932

Q35111925-14010258-9CCF-4A6B-A611-513686B13C05

P356

1078-0432.CCR-14-1380

P1433

Clinical Cancer Research

P1476

First-in-human dose study of t ...... th advanced cancer and glioma.

@en

P2093

Analia Azaro

http://www.w3.org/2001/XMLSchema#string

Ann L Cleverly

http://www.w3.org/2001/XMLSchema#string

Durisala Desaiah

http://www.w3.org/2001/XMLSchema#string

Elisabet Sicart

http://www.w3.org/2001/XMLSchema#string

Emiliano Calvo

http://www.w3.org/2001/XMLSchema#string

Irene Braña

http://www.w3.org/2001/XMLSchema#string

Ivelina Gueorguieva

http://www.w3.org/2001/XMLSchema#string

Jaishri Blakeley

http://www.w3.org/2001/XMLSchema#string

Joan Seoane

http://www.w3.org/2001/XMLSchema#string

Jordi Rodon

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated genomic analysis of human glioblastoma multiforme

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

TGFbeta signaling in growth control, cancer, and heritable disorders

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma

TGF-beta signaling in tumor suppression and cancer progression

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

P304

553-560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-1380

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25424852

http://www.w3.org/2001/XMLSchema#string

P921

P932

4337847

http://www.w3.org/2001/XMLSchema#string